Article Sidebar
Published:
Jun 14, 2018Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Salicylamide purpura
Abstract
The purpose of tills article is to draw attention to a thrombocytopenic purpura which has resulted from the taking of salicylamide.
This drug is advertised in the lay press as 'R12' and claims are made for it as a drug which 'not only relieves the pain of rheumatism but actually reduces swelling by dispersing the uric acid accumulation ... Locked joints become free again.' It is further said to be 'absolutely harmless'. The drug was self-administered in the two cases which came under the author's attention, and the aetiology of cases presenting with a severe haemorrhagic episode may prove baffling, especially as patients are usually loath to admit to taking such self-prescribed remedies.
